Tag Archives: Revance Therapeutics

Revance Therapeutics (RVNC) Gets a Buy Rating from Needham

Needham analyst Serge Belanger maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) on February 24 and set a price target of $36.00. The company’s shares closed last Monday at $24.76. According to TipRanks.com, Belanger is a 4-star

Analysts Are Bullish on Top Healthcare Stocks: Revance Therapeutics (RVNC), Paratek Pharmaceuticals (PRTK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revance Therapeutics (RVNC – Research Report), Paratek Pharmaceuticals (PRTK – Research Report) and Bioxcel Therapeutics (BTAI – Research Report) with bullish sentiments.

Mizuho Securities Keeps Their Buy Rating on Revance Therapeutics (RVNC)

Mizuho Securities analyst Difei Yang reiterated a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $39.00. The company’s shares closed last Monday at $22.20, close to its 52-week high of $23.43. According

Revance Therapeutics (RVNC) Received its Third Buy in a Row

After Needham and Stifel Nicolaus gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Revance Therapeutics today and set a price

Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (NASDAQ: RVNC) and Celgene (NASDAQ: CELG)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (RVNC – Research Report) and Celgene (CELG – Research Report). Revance Therapeutics (RVNC) In a report released today, Difei Yang from

Revance Therapeutics (RVNC) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $34.00. The company’s shares closed last Monday at $12.70, close to its 52-week low of $9.88. According